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Abstract
Background: InterVA is a probabilistic method for interpreting verbal autopsy (VA) data. It uses a priori approximations of
probabilities relating to diseases and symptoms to calculate the probability of specific causes of death given reported
symptoms recorded in a VA interview. The extent to which InterVA’s ability to characterise a population’s mortality
composition might be sensitive to variations in these a priori probabilities was investigated.
Methods: A priori InterVA probabilities were changed by 1, 2 or 3 steps on the logarithmic scale on which the original
probabilities were based. These changes were made to a random selection of 25% and 50% of the original probabilities,
giving six model variants. A random sample of 1,000 VAs from South Africa, were used as a basis for experimentation and
were processed using the original InterVA model and 20 random instances of each of the six InterVA model variants. Rank
order of cause of death and cause-specific mortality fractions (CSMFs) from the original InterVA model and the mean,
maximum and minimum results from the 20 randomly modified InterVA models for each of the six variants were compared.
Results: CSMFs were functionally similar between the original InterVA model and the models with modified a priori
probabilities such that even the CSMFs based on the InterVA model with the greatest degree of variation in the a priori
probabilities would not lead to substantially different public health conclusions. The rank order of causes were also similar
between all versions of InterVA.
Conclusion: InterVA is a robust model for interpreting VA data and even relatively large variations in a priori probabilities do
not affect InterVA-derived results to a great degree. The original physician-derived a priori probabilities are likely to be
sufficient for the global application of InterVA in settings without routine death certification.
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Introduction
Population-level cause-of-death data are a crucial component of
understanding health and disease and formulating effective public
health programs. Yet having one’s death counted and assigned a
cause, information critical to individual and population-level
understandings of mortality, remains confined to a privileged
minority of the world’s population. For the majority of people in
low-income settings who die at home without an attending
physician and where deaths are not routinely recorded or classified
by cause, verbal autopsy (VA) methods are the only viable means
of deriving probable cause of death.
Though specific procedures can vary, VA is essentially the
process of interviewing family, friends or carers after a death has
occurred to find out about the circumstances of death. These data
are normally gathered by lay interviewers and once gathered, the
data are interpreted to derive possible cause(s) of death [1].
Physician review of VA data to assign a cause of death is historically
the most commonly used method to derive possible causes, despite
considerable concerns over the reliability and inefficient nature of
this method. Recent advances in the development of computer-
based probabilistic methods for interpreting VA are an attractive
alternative to case-by-case physician interpretation. Such methods
have the considerable advantage of being faster, cheaper and more
internally consistent than physician review, offering new opportu-
nities for timely and comparable cause-specific mortality estimates
across time and space. High levels of agreement between
probabilistic methods and physician review have been demonstrat-
ed in a number of different contexts and have highlighted important
advantages of probabilistic methods [2–6].
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for interpreting VA data and has been applied in numerous
settings in Africa and Asia [7–10]. InterVA is based on
approximations of the probabilities of specific causes and specific
symptoms among all deaths, as well as the probabilities of specific
symptoms given that an individual has died from a specific cause.
Using Bayes’ theorem, it is then possible to calculate the
probability of specific causes given reported symptoms recorded
in a VA interview. In other words, InterVA obtains posterior
probabilities of specific causes of death given an a priori distribution
of the probabilities of causes and signs and symptoms of causes.
Designed from the outset as a tool that can be applied in any
setting where VAs are used, the a priori probabilities used to
calculate the likelihoods of specific causes of death given a
particular set of reported signs and symptoms are approximations
that were agreed upon by a physician panel that included
practitioners from a range of medical specialisations and
geographic regions [2]. However, the extent to which InterVA’s
ability to characterise a population’s mortality composition is
sensitive to variations in these a priori probabilities, as might reflect
regional differences in disease and symptom prevalences or indeed
the opinions of a different panel of physicians, is unknown.
Therefore, using a sample of deaths from the Agincourt Health
and Socio-demographic Surveillance Site in rural South Africa as
a test dataset for modelling, this study aims to test the sensitivity of
InterVA to variations in the a priori probabilities that it uses. This
has implications for the fundamental assumptions of InterVA and
its use in a wide variety of settings with differing underlying
mortality profiles. It is important to note that, as a methodological
investigation, this paper does not set out to characterise the
epidemiology or cause of death distribution of the Agincourt
population.
Methods
InterVA
Applying Bayes’ theorem, the computer-based InterVA ap-
proach calculates the probability of each of a finite list of causes (C)
given the presence of specific signs, symptoms or indicators (I), for
which the probability of reporting each indicator given a specific
cause (P(I|C)) and the population-level probability of each cause
among all deaths (P(C)) has been estimated [11]. In mathematical
terms:
P(CjI)~
P(I C j )xP(C)
P(I C j )xP(C)zP(I ! j C)xP(!C)
where P(!C) is the probability of not (C).
The prior probabilities P(I|C) and P(C) are derived from an
expert physician consensus process whereby probabilities were
estimated based on a range of thirteen approximate quantitative
probabilities associated with semi-qualitative descriptors that
included ‘impossible’ (P=0), ‘uncommon’ (P=0.001, P=0.002
or P=0.005), ‘moderately often’ (P=0.01, P=0.02 or P=0.05),
‘frequently’ (P=0.1, P=0.2 or P=0.5) and ‘inevitable’ (P=1).
Thus, each step increase on the scale results in an approximate
doubling of the probability. The physicians involved in this process
were selected from a range of settings and clinical backgrounds,
thus minimising the risk of developing InterVA based too closely to
the disease prevalence of any one geographical region or medical
discipline [2].
Conceptually, InterVA is based on a matrix of a priori
probabilities. The current InterVA model (version 3.2) is based
on 35 possible causes of death, which can be considered as
columns in the matrix, and 106 signs or symptoms (collectively
referred to as ‘indicators’), which can be considered as rows in the
matrix. The set of indicators and causes included in the model was
influenced by established VA questionnaires and the expert
consensus process described above, and can be viewed elsewhere
[2] and online (www.interva.net). The matrix also includes one
additional row and one additional column for the independent,
baseline probabilities of causes (P(C)) and indicators (P(I)) among
all deaths in a population. The cells in the matrix must then be
populated with the probabilities of specific indicators given specific
causes (P(I|C) (Table 1). As such the InterVA probability matrix is
comprised of 3,852 cells (36 columns by 107 rows) each with a
physician-consensus probability value.
Using the above equation, the probability of each cause can be
determined based on the indicators reported in a VA. Symptoms,
histories and circumstances of death reported in either the open
narrative or closed questions in VA interviews can be utilised.
InterVA displays up to three most likely causes of death with
corresponding likelihoods and an overall certainty factor for each
death. Fewer than three causes will be displayed if the probability
of the third (or second) cause is less than 50% of the probability of
the preceding cause. Cases with insufficient VA data to decisively
determine the cause probabilities are identified by InterVA as
‘indeterminate’. Each assigned cause is associated with a
likelihood, and the sum of likelihoods of assigned causes has a
maximum value of 1.00. If the sum of likelihoods of assigned
causes is less than 1.00, then the difference reflects a lack of
certainty about the overall cause, which can be considered as an
indeterminate component of the case [9].
Random modifications to a priori probabilities
To assess the robustness of InterVA to variations in the a priori
probabilities, routines were written using Microsoft Visual FoxPro
software to select random samples of 25% and 50% of the matrix
cells and change the a priori probabilities. Approximately half of the
randomly selected cells had their probability increased and half
had their probability decreased. Three different degrees of
modification were used independently, i.e. up to 1, 2 and 3 steps
on the logarithmic scale on which the original probabilities were
based. Table 2 illustrates the procedure for each level of
modification. No probabilities were made to equal 1 (inevitable)
or 0 (impossible) and if probabilities could not be increased or
decreased by the specified number of steps because they were
already at or close to the maximum or minimum, they were
increased or decreased by the maximum number of steps possible.
If the original a priori probabilities could not increase or decrease at
all, the direction of change was reversed. For example, a selected
Table 1. Illustration of the InterVA probability matrix of a
priori probabilities.
Causes
C1 C2 ... C36
P(C1)P ( C 2) ... P(C36)
I1 P(I1) P(I1|C1)P ( I 1|C2) ... P(I1|C36)
I2 P(I2) P(I2|C1)P ( I 2|C2) ... P(I2|C36)
Indicators I3 P(I3) P(I3|C1)P ( I 3|C2) ... P(I3|C36)
... ... ... ... ... ...
In P(I106) P(I106|C1)P ( I 106|C2) ... P(I106|C36)
doi:10.1371/journal.pone.0027200.t001
InterVA Robustness
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to be increased by three steps will be decreased by 3 steps instead.
This process was repeated twenty times for each degree of
modification of the probability matrix thus generating 120 new
matrices (i.e.20 matrices with 25% of the cells modified by 1 step,
20 matrices with 50% of the cells modified by 1 step, 20 matrices
with 25% of the cells modified by 2 steps, and so on).
The test dataset
The original and modified InterVA models were applied to a
random sample of 1000 all-age, all-sex deaths occurring between
1992 and 2006 in the Agincourt Health and Socio-demographic
Surveillance System (HDSS) in South Africa and for which VA
data were available. The Agincourt HDSS is part of the
INDEPTH network (www.indepth-network.org) and has moni-
tored a contiguous population of around 70,000 since 1992. The
background to this work as well as several cause-specific mortality
analyses are described in detail elsewhere [9,12–14]. The sample
of 1,000 completed VAs represents approximately 17% of the
available VA data, which is considered likely to provide an
adequate representation of the range of VA-derived symptom
profiles and major causes of death within this population.
Sensitivity assessment
Population cause-specific mortality fractions (CSMFs) were
derived for the same 1,000 VA cases for each randomised instance
of the six InterVA model variants. To derive population level
CSMFs, the sum of likelihoods for each cause category (including
indeterminate) was divided by the sum of the likelihoods for all
causes, thus splitting individual deaths between multiple causes
weighted by the specific cause probabilities. The sum of all
fractions in each cause category divided by the total number of
deaths represents the population CSMF. The mean CSMFs and
the rank order of causes from the 20 samples for each variation of
the InterVA probability matrix were compared against each other
and the results derived from the original, physician-consensus
based model to assess functional (non-statistical) similarities.
Ethical Approval
Within the Agincourt Health and Socio-demographic Surveil-
lance project, informed consent is obtained verbally at the
individual and household levels at every follow-up visit. Commu-
nity consent from civic and traditional leadership was secured
verbally at the start of surveillance and is reaffirmed during annual
information feedback meetings. Written consent is not sought due
to issues relating to literacy, the impracticalities of seeking repeated
signed consent in a long running, prospective surveillance project,
and a degree of local reluctance to signing forms, which relates to
historical political experiences in South Africa’s recent past. This
process of informed consent and all surveillance-based studies in
the Agincourt sub-district were reviewed and approved by the
Committee for Research on Human Subjects (Medical) of the
University of the Witwatersrand, Johannesburg, South Africa
(protocol M960720).
Results
Detailed CSMFs based on the original InterVA model using
physician-derived a priori probabilities and the mean, minimum
and maximum of twenty analyses of each of the modified
probability model variants are shown in Table S1. Mean CSMFs
were functionally similar between the original InterVA and each of
the modified versions of it.
When aggregated into broad cause categories, for which public
health interventions and health service implications would not
differ greatly, it was clear that any conclusions or understandings
of cause-distributions based on any of the probability matrices
would not differ greatly (Figures 1 & 2).
The rank order of the top ten causes of death according to each
permutation of the probability matrix is shown in Figure 3. There
was good overall agreement between all variations of InterVA; in
all but one model, 9 out of 10 causes were common between the
modified models and the original. The lowest level of agreement
was for 50% variation at a maximum of 2 steps, but the agreement
was still high, with 8 out of 10 causes common between the
modified InterVA and the original.
Table 2. Probability scale and qualitative descriptors on which a priori InterVA probabilities are based and a demonstration of how
original probabilities were modified to varying degrees.
Qualitative
Descriptor
Original Quantitative
Probability
Increase by 1
Step
Decrease by 1
Step
Increase by 2
Steps
Decrease by 2
Step
Increase by 3
Steps
Decrease by 3
Step
Inevitable* 0.99 0.5
a 0.5 0.2
a 0.2 0.1
a 0.1
Frequently 0.5 0.2
a 0.2 0.1
a 0.1 0.05
a 0.05
0.2 0.5 0.1 0.5
c 0.05 0.5
c 0.02
0.1 0.2 0.05 0.5 0.02 0.5
c 0.01
Moderately Often 0.05 0.1 0.02 0.2 0.01 0.5 0.005
0.02 0.05 0.01 0.1 0.005 0.2 0.002
0.01 0.02 0.005 0.05 0.002 0.1 0.001
Uncommon 0.005 0.01 0.002 0.02 0.001 0.05 0.001
d
0.002 0.005 0.001 0.01 0.001
d 0.02 0.001
d
0.001 0.002 0.002
b 0.005 0.005
b 0.01 0.01
b
Impossible* 0 0.001 0.001
b 0.002 0.002
b 0.005 0.005
b
*No probabilities were made to be ‘‘inevitable’’ or ‘‘impossible’’.
aWhere probabilities could not be increased they were decreased by an equivalent amount.
bWhere probabilities could not be decreased they were increased by an equivalent amount.
cWhere probabilities could not be increased by the full amount they were increased by as much as possible without violating *.
dWhere probabilities could not be decreased by the full amount they were decreased by as much as possible without violating *.
doi:10.1371/journal.pone.0027200.t002
InterVA Robustness
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From the outset, InterVA was designed to be a generic tool and
not context-dependent. However, the extent to which a generic
probability tool can be developed when underlying likelihoods of
certain symptoms and causes inevitably vary across populations is
yet to be established. With some important exceptions, large
modifications to the a priori probabilities on which InterVA derives
likely causes of death, resulting CSMFs, broad cause distributions
and the rank order of causes did not generally differ to such an
extent that one’s overall impression of the major mortality burdens
and public health priorities in the population would be likely to
differ. This empirical study thus demonstrates a high degree of
robustness of InterVA to variations in the a priori probability
matrix, with important implications for the global application of
the method.
Some important outliers were observed in the results. The
maximum relative difference in a proportion attributed to a
specific cause category compared to the original InterVA model
was 215 times for malaria deaths (Figure 3, 50% of a priori
probabilities changed by up to 3 steps). The extent to which such a
large relative difference matter, however, depends on the original,
or baseline, CSMF to which it relates and this 215-fold increase in
the proportion of malaria deaths equates to an absolute increase of
just over 2% compared to the original malaria mortality fraction.
Conversely, absolute differences can be large and of public health
importance if relative differences are small and the original CSMF
is large. For example, the largest absolute difference observed was
a 23% increase in the HIV-related mortality fraction (50% of a
priori probabilities changed by up to 3 steps), representing an
approximately 4-fold increase in this cause, with obvious public
health implications. These results support the idea that it may be
necessary to set InterVA a priori cause probabilities (P(C)) to
account for local variations in cause prevalences only for those
causes that are have a high baseline prevalence in some settings
but a low prevalence in others.
Based on this reasoning the current InterVA model (version 3.2)
expects inputs of ‘‘high’’ and ‘‘low’’ settings for HIV and malaria
and adjusts the baseline probabilities accordingly. Although other
causes of death included in InterVA are also likely to vary by at
least an order of magnitude between populations, such as
haemoglobinopathies or homicide, these causes are associated
with such specific signs, symptoms and demographics that the
need to allow for population differences is likely to be minimal.
This study limited the degree of variation in a priori probabilities
at a maximum of three steps on the probability scale – equivalent
to an order of magnitude. Though a greater degree of
modification was possible, it is unlikely that any similarly diverse
panel of physicians would reach conclusions on underlying
population cause and indicator likelihoods that would differ by
Figure 1. Broad cause distributions based on original InterVA and a modified version with 25% of a priori probabilities modified by
upto 1, 2 and 3 steps.
doi:10.1371/journal.pone.0027200.g001
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upto 1, 2 and 3 steps.
doi:10.1371/journal.pone.0027200.g002
Figure 3. Top 10 cause-of-death categories based on InterVA and the physician-consensus a priori probabilities and the randomly
modified probability matrices. Green shading represents an exact match, pink shading represents a top-10 cause but at a different rank, red
shading represents a cause not included in the original top-10.
doi:10.1371/journal.pone.0027200.g003
InterVA Robustness
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above. Given the findings that approximate, ‘‘ball-park’’ estima-
tions of a priori probabilities are sufficient to achieve a workable
model it is not surprising that the very first prototype of InterVA,
which was based solely on the personal experiences and
assumptions of an experienced epidemiologist, performed reason-
ably well [3]. Subsequent Delphi-style consensus building among a
panel of physicians did improve the model’s performance in
relation to physician review [2]. However, observed improvements
may have been as much due to the addition of new indicators and
cause categories to the model as to modifications of a priori
probabilities. Either way, any concerns that a different InterVA
model would have resulted from the involvement of a different
panel of physicians seem unfounded given the large degree of
variation in underlying probabilities that is needed to meaningfully
alter the output of InterVA.
The InterVA method does have limitations. For example, not
all indicators built into InterVA are available in the Agincourt VA
data and similarly, not all information gathered by the Agincourt
VA questionnaire can be utilised by InterVA. In general the
consequences of this are likely to lead to lower overall certainty of
derived causes of death and the fact that InterVA cause
probabilities are only modified by affirmative answers minimises
the effects of missing or negative information from VA forms. In
relation to the current study, it is possible that matrix probabilities
that ultimately were not utilised when applied to the Agincourt
data were included in the sample of modified probabilities. This is
a limitation of the study and in theory could have underestimated
the effect of a priori probability modification on resulting CSMFs.
However, the repetition of each analysis twenty times, each time
taking a new sample of matrix probability cells is likely to have
reduced any such effects.
In presenting the considerable consistency of results from the
InterVA model from these sensitivity analyses of randomly
induced variations in the model’s probability matrix, it is also
important to stress that the model has previously been demon-
strated to reveal very considerable differences in CSMFs across
different settings in Africa and Asia [9]. It is therefore not the case
that the InterVA model tends to reduce any VA data to a common
pattern of causes of death, and thus the lack of variation in these
sensitivity analyses does not arise out of an inherent property of the
InterVA model.
Whilst this study shows that approximations of underlying
probabilities in the InterVA model are sufficient to establish a
workable model, the probabilities are based to some extent on the
assumption that responses to each indicator are independent of all
other indicators, which, in reality, is flawed. Other techniques are
being developed that use facility-data to establish the probability of
reporting specific symptoms given a specific cause [15,16]. These
symptom properties then allow population and individual-level
cause patterns to be determined from VA data from a second
dataset from the population of interest. Such methods are
theoretically appealing but are ultimately limited in that they
depend upon the availability of high quality facility-based or valid
mortality data for modelling – a highly context-dependant pre-
requisite that cannot readily be met in the majority of settings that
need to use VA methods [1]. Furthermore, as the current study
suggests, the added complexity and greater precision of such
techniques may have little consequence on the ultimate conclu-
sions and utility of VA-derived cause-of-death profiles.
VA is often considered a blunt tool that lacks precision.
However, this need not detract from its utility for health
monitoring and service planning in resource-poor settings that
otherwise have no means of knowing and monitoring causes of
death in their populations. Indeed, by keeping in mind who needs
cause of death data and for what purposes [17], reasonable
degrees of imprecision become acceptable and the criteria of
efficiency, affordability and reliability become paramount. VA is
fundamentally a population-level, public health tool; thus methods
which reliably interpret VA data to estimate population-level
causes of death with an appreciation for inevitable degrees of
uncertainty are highly desirable and InterVA offers one such
method that, based on this study’s findings, can be applied with
confidence in the diverse range of settings where deaths and their
causes are not counted.
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